16 results
Thumbnail

D3.84 - Delayed hypersensitivity to hydroxychloroquine with positive patch test

Thumbnail

D3.85 - Evaluation of a new Multiplex Allergen Test Kit for the simultaneous detection of allergen specific IgE

Thumbnail

D3.87 - Assessing the agreement between skin prick test and specific-IgE for ten common food allergens in infants

Thumbnail

D3.89 - Unexpected Culprit: The Role of Acrylates in Recurrent Anaphylaxis and Antibiotic Hypersensitivity

Thumbnail

D3.91 - Safety of Skin Prick Tests: more than 30 years of spontaneous data from real practice

Thumbnail

D3.94 - Optimizing the Diagnosis and Treatment of Psoriasis Associated with Streptococcal Infection

Thumbnail

D3.88 - 5-Year Metal Patch Testing Analysis of a Portuguese Immunology an Allergology Center: Allergen relevance and Cluster identification

Thumbnail

D3.364 - Effect of Omalizumab on Inflammatory and Immune Biomarkers in Mast Cell-Mediated Angioedema

Thumbnail

D3.358 - The impact of limited access to On-Demand Treatment for Hereditary Angioedema on Quality of life: a comparison between two income settings

Thumbnail

D3.359 - Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Thumbnail

D3.362 - Use and safety of canakinumab during pregnancy

Thumbnail

D3.363 - Vitamin D3 deficiency promotes epithelial-to-mesenchymal transition and thus favours pulmonary fibrosis development in the murine model of hypersensitivity pneumonitis

Thumbnail

D3.365 - The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Thumbnail

D3.366 - Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Thumbnail

D3.367 - Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Thumbnail

D3.368 - Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year